Apricus Biosciences (NASDAQ: APRI) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares Apricus Biosciences and Taro Pharmaceutical Industries’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apricus Biosciences $5.76 million 2.32 -$7.43 million $0.46 1.78
Taro Pharmaceutical Industries $879.39 million 4.54 $456.35 million $5.15 19.35

Taro Pharmaceutical Industries has higher revenue and earnings than Apricus Biosciences. Apricus Biosciences is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Apricus Biosciences and Taro Pharmaceutical Industries, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apricus Biosciences 0 1 1 0 2.50
Taro Pharmaceutical Industries 0 1 0 0 2.00

Apricus Biosciences presently has a consensus price target of $1.00, indicating a potential upside of 22.41%. Given Apricus Biosciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Apricus Biosciences is more favorable than Taro Pharmaceutical Industries.

Risk and Volatility

Apricus Biosciences has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Insider & Institutional Ownership

24.4% of Apricus Biosciences shares are held by institutional investors. Comparatively, 11.5% of Taro Pharmaceutical Industries shares are held by institutional investors. 3.6% of Apricus Biosciences shares are held by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


This table compares Apricus Biosciences and Taro Pharmaceutical Industries’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apricus Biosciences N/A -179.12% -130.86%
Taro Pharmaceutical Industries 30.43% 11.35% 10.33%


Taro Pharmaceutical Industries beats Apricus Biosciences on 9 of the 14 factors compared between the two stocks.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company’s owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company’s other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.